{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:10:23Z","timestamp":1789747823066,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00894-022-05185-w","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T05:02:43Z","timestamp":1655528563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Repurposing benzbromarone as antifolate to develop novel antifungal therapy for Candida albicans"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-5475","authenticated-orcid":false,"given":"Somdutt","family":"Mujwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avanish","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"key":"5185_CR1","doi-asserted-by":"crossref","unstructured":"DeJarnette C, Luna-Tapia A, Estredge LR, Palmer GEJM (2020) Dihydrofolate reductase is a valid target for antifungal development in the human pathogen Candida albicans. 5 (3)","DOI":"10.1128\/mSphere.00374-20"},{"key":"5185_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1554","author":"K Benedict","year":"2020","unstructured":"Benedict K, Kobayashi M, Garg S, Chiller T, Jackson BR (2020) Symptoms in blastomycosis, coccidioidomycosis, and histoplasmosis versus other respiratory illnesses in commercially insured adult outpatients, United States, 2016\u20132017. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa1554","journal-title":"Clin Infect Dis"},{"key":"5185_CR3","doi-asserted-by":"crossref","unstructured":"Nucci M, Barreiros G, Guimar\u00e3es LF, Deriquehem VA, Casti\u00f1eiras AC, Nou\u00e9r SAJM (2020) Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic","DOI":"10.1111\/myc.13225"},{"issue":"10","key":"5185_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.cmi.2020.06.025","volume":"26","author":"S Hughes","year":"2020","unstructured":"Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP (2020) Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 26(10):1395\u20131399. https:\/\/doi.org\/10.1016\/j.cmi.2020.06.025","journal-title":"Clin Microbiol Infect"},{"issue":"10223","key":"5185_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"issue":"14","key":"5185_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMoa040446","volume":"351","author":"TJ Walsh","year":"2004","unstructured":"Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391\u20131402. https:\/\/doi.org\/10.1056\/NEJMoa040446","journal-title":"N Engl J Med"},{"key":"5185_CR7","doi-asserted-by":"publisher","unstructured":"DeJarnette C, Luna-Tapia A, Estredge LR, Palmer GE (2020) Dihydrofolate reductase is a valid target for antifungal development in the human pathogen Candida albicans. mSphere 5 (3). https:\/\/doi.org\/10.1128\/mSphere.00374-20","DOI":"10.1128\/mSphere.00374-20"},{"key":"5185_CR8","doi-asserted-by":"publisher","unstructured":"Posteraro B, Torelli R, Vella A, Leone PM, De Angelis G, De Carolis E, Ventura G, Sanguinetti M, Fantoni M (2020) Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report. J Fungi (Basel) 6 (3). https:\/\/doi.org\/10.3390\/jof6030163","DOI":"10.3390\/jof6030163"},{"issue":"12","key":"5185_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","volume":"68","author":"BJ Kullberg","year":"2019","unstructured":"Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L, Rotstein C, Sobel JD, Herbrecht R, Rahav G, Jaruratanasirikul S, Chetchotisakd P, Van Wijngaerden E, De Waele J, Lademacher C, Engelhardt M, Kovanda L, Croos-Dabrera R, Fredericks C, Thompson GR (2019) Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida Infections: the ACTIVE trial. Clin Infect Dis 68(12):1981\u20131989. https:\/\/doi.org\/10.1093\/cid\/ciy827","journal-title":"Clin Infect Dis"},{"issue":"10","key":"5185_CR10","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1128\/AAC.00726-15","volume":"59","author":"X Li","year":"2015","unstructured":"Li X, Hou Y, Yue L, Liu S, Du J, Sun S (2015) Potential Targets for antifungal drug discovery based on growth and virulence in Candida albicans. Antimicrob Agents Chemother 59(10):5885\u20135891. https:\/\/doi.org\/10.1128\/AAC.00726-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"5185_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/adt.2019.944","volume":"17","author":"S Mujwar","year":"2019","unstructured":"Mujwar S, Deshmukh R, Harwansh RK, Gupta JK, Gour A (2019) Drug repurposing approach for developing novel therapy against mupirocin-resistant Staphylococcus aureus. Assay Drug Dev Technol 17(7):298\u2013309. https:\/\/doi.org\/10.1089\/adt.2019.944","journal-title":"Assay Drug Dev Technol"},{"issue":"7","key":"5185_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1089\/adt.2020.976","volume":"18","author":"S Mujwar","year":"2020","unstructured":"Mujwar S, Kumar V (2020) Computational drug repurposing approach to identify potential fatty acid-binding protein-4 inhibitors to develop novel antiobesity therapy. Assay Drug Dev Technol 18(7):318\u2013327","journal-title":"Assay Drug Dev Technol"},{"key":"5185_CR13","doi-asserted-by":"crossref","unstructured":"Jain R, Mujwar SJSC (2020) Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. 31 (6):2487\u20132499","DOI":"10.1007\/s11224-020-01605-w"},{"issue":"6","key":"5185_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/adt.2019.943","volume":"17","author":"K Shah","year":"2019","unstructured":"Shah K, Mujwar S, Gupta JK, Shrivastava SK, Mishra P (2019) Molecular docking and in silico cogitation validate mefenamic acid prodrugs as human cyclooxygenase-2 inhibitor. Assay Drug Dev Technol 17(6):285\u2013291. https:\/\/doi.org\/10.1089\/adt.2019.943","journal-title":"Assay Drug Dev Technol"},{"key":"5185_CR15","doi-asserted-by":"crossref","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PEJNar (2000) The protein data bank. 28 (1):235\u2013242","DOI":"10.1093\/nar\/28.1.235"},{"issue":"6","key":"5185_CR16","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1021\/jm401916j","volume":"57","author":"N Gd","year":"2014","unstructured":"Gd N, Paulsen JL, Viswanathan K, Keshipeddy S, Lombardo MN, Zhou W, Lamb KM, Sochia AE, Alverson JB, Priestley ND, Wright DL, Anderson AC (2014) Propargyl-linked antifolates are dual inhibitors of Candida albicans and Candida glabrata. J Med Chem 57(6):2643\u20132656. https:\/\/doi.org\/10.1021\/jm401916j","journal-title":"J Med Chem"},{"issue":"13","key":"5185_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera\u2013a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605\u20131612. https:\/\/doi.org\/10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"issue":"3","key":"5185_CR18","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.13005\/bbra\/1889","volume":"12","author":"P Pradhan","year":"2015","unstructured":"Pradhan P, Soni NK, Chaudhary L, Mujwar S, Pardasani KR (2015) In-silico prediction of riboswitches and design of their potent inhibitors for H1N1, H2N2 and H3N2 strains of influenza virus. Biosci, Biotechnol Res Asia 12(3):2173\u20132186","journal-title":"Biosci, Biotechnol Res Asia"},{"key":"5185_CR19","doi-asserted-by":"publisher","DOI":"10.2174\/1573409915666190820144759","author":"SK Kaushal","year":"2019","unstructured":"Kaushal SK, Brijendra S, Mujwar S, Prakash BS (2019) Molecular docking based analysis to elucidate the DNA topoisomerase IIbeta as the potential target for the Ganoderic acid, a natural therapeutic agent in cancer therapy. Curr Comput Aided Drug Des. https:\/\/doi.org\/10.2174\/1573409915666190820144759","journal-title":"Curr Comput Aided Drug Des"},{"issue":"6","key":"5185_CR20","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1007\/s11224-020-01605-w","volume":"31","author":"R Jain","year":"2020","unstructured":"Jain R, Mujwar S (2020) Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19. J Structural Chemistry 31(6):2487\u20132499","journal-title":"J Structural Chemistry"},{"issue":"3","key":"5185_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1504\/IJCBDD.2016.078278","volume":"9","author":"A Kaur","year":"2016","unstructured":"Kaur A, Mujwar S, Adlakha N (2016) In-silico analysis of riboswitch of Nocardia farcinica for design of its inhibitors and pharmacophores. International Journal of Computational Biology Drug Design 9(3):261\u2013276","journal-title":"International Journal of Computational Biology Drug Design"},{"issue":"5","key":"5185_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc 11(5):905\u2013919. https:\/\/doi.org\/10.1038\/nprot.2016.051","journal-title":"Nat Protoc"},{"issue":"4","key":"5185_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1504\/IJCBDD.2015.073671","volume":"8","author":"SPK Mujwar","year":"2015","unstructured":"Mujwar SPK (2015) Prediction of riboswitch as a potential drug target and design of its optimal inhibitors for Mycobacterium tuberculosis. Int J Comput Biol Drug Des 8(4):326\u2013347","journal-title":"Int J Comput Biol Drug Des"},{"issue":"1","key":"5185_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1166\/jmihi.2015.1358","volume":"5","author":"SPK Mujwar","year":"2015","unstructured":"Mujwar SPK (2015) Prediction of riboswitch as a potential drug target for infectious diseases: an insilico case study of anthrax. Journal of Medical Imaging and Health Informatics 5(1):7\u201316","journal-title":"Journal of Medical Imaging and Health Informatics"},{"issue":"7","key":"5185_CR25","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1089\/adt.2020.977","volume":"18","author":"K Shah","year":"2020","unstructured":"Shah K, Mujwar S, Krishna G, Gupta JK (2020) Computational design and biological depiction of novel naproxen derivative. Assay Drug Dev Technol 18(7):308\u2013317","journal-title":"Assay Drug Dev Technol"},{"issue":"9","key":"5185_CR26","first-page":"191","volume":"7","author":"N Soni","year":"2015","unstructured":"Soni N, Pardasani KR, Mujwar S (2015) Insilico analysis of dietary agents as anticancer inhibitors of insulin like growth factor 1 receptor (IGF1R). J Pharm Pharm Sci 7(9):191\u2013196","journal-title":"J Pharm Pharm Sci"},{"key":"5185_CR27","doi-asserted-by":"publisher","first-page":"108897","DOI":"10.1016\/j.biopha.2019.108897","volume":"115","author":"N Minaz","year":"2019","unstructured":"Minaz N, Razdan R, Hammock BD, Mujwar S, Goswami SK (2019) Impact of diabetes on male sexual function in streptozotocin-induced diabetic rats: protective role of soluble epoxide hydrolase inhibitor. Biomed Pharmacother 115:108897. https:\/\/doi.org\/10.1016\/j.biopha.2019.108897","journal-title":"Biomed Pharmacother"},{"key":"5185_CR28","doi-asserted-by":"crossref","unstructured":"Mujwar SJCiB, Medicine (2021) Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2.104748","DOI":"10.1016\/j.compbiomed.2021.104748"},{"key":"5185_CR29","unstructured":"System SR-DMD (2020) Maestro-desmond interoperability tools, Schr\u00f6dinger, New York, NY, 2021. D. E. Shaw Res, New York, NY, 2021"},{"key":"5185_CR30","doi-asserted-by":"crossref","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Kontek RJBeBA-RoC (2022) Cyclin-dependent kinases in DNA damage response.188716","DOI":"10.1016\/j.bbcan.2022.188716"},{"key":"5185_CR31","doi-asserted-by":"crossref","unstructured":"Kciuk M, Gieleci\u0144ska A, Mujwar S, Mojzych M, Kontek RJIJoMS (2022) Cyclin-dependent kinase synthetic lethality partners in DNA damage response. 23 (7):3555","DOI":"10.3390\/ijms23073555"},{"key":"5185_CR32","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.compbiomed.2021.104748","volume":"136","author":"S Mujwar","year":"2021","unstructured":"Mujwar S (2021) Computational repurposing of tamibarotene against triple mutant variant of SARS-CoV-2. Comput Biol Med 136:104748. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104748","journal-title":"Comput Biol Med"},{"issue":"4","key":"5185_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4103\/bbrj.bbrj_56_21","volume":"5","author":"S Mujwar","year":"2021","unstructured":"Mujwar S (2021) Computational bioprospecting of andrographolide derivatives as potent cyclooxygenase-2 inhibitors. Biomed Biotechnol Res J 5(4):446","journal-title":"Biomed Biotechnol Res J"},{"key":"5185_CR34","doi-asserted-by":"publisher","unstructured":"Mujwar S, Harwansh RK (2022) In silico bioprospecting of taraxerol as a main protease inhibitor of SARS-CoV-2 to develop therapy against COVID-19. Struct Chem :1\u201312. https:\/\/doi.org\/10.1007\/s11224-022-01943-x","DOI":"10.1007\/s11224-022-01943-x"},{"key":"5185_CR35","doi-asserted-by":"crossref","unstructured":"Lee DG, Kim HK, Am Kim S, Park Y, Park S-C, Jang S-H, Hahm K-SJB, communications br (2003) Fungicidal effect of indolicidin and its interaction with phospholipid membranes. 305 (2):305\u2013310","DOI":"10.1016\/S0006-291X(03)00755-1"},{"key":"5185_CR36","doi-asserted-by":"crossref","unstructured":"Jahn B, Martin E, Stueben A, Bhakdi SJJoCM (1995) Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide assay. 33 (3):661\u2013667","DOI":"10.1128\/jcm.33.3.661-667.1995"},{"key":"5185_CR37","doi-asserted-by":"crossref","unstructured":"Al-Hatmi AM, Mohsin J, Al-Huraizi A, Khamis FJJoI (2021) COVID-19 associated invasive candidiasis. 82 (2):e45-e46","DOI":"10.1016\/j.jinf.2020.08.005"},{"key":"5185_CR38","doi-asserted-by":"crossref","unstructured":"Buehler PK, Zinkernagel AS, Hofmaenner DA, Garcia PDW, Acevedo CT, G\u00f3mez-Mejia A, Shambat SM, Andreoni F, Maibach MA, Bartussek JJCRM (2021) Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients. 2 (4):100229","DOI":"10.1016\/j.xcrm.2021.100229"},{"key":"5185_CR39","doi-asserted-by":"crossref","unstructured":"Kordalewska M, Guerrero KD, Garcia-Rubio R, Jim\u00e9nez-Ortigosa C, Mediavilla JR, Cunningham MH, Hollis F, Hong T, Chow KF, Kreiswirth BNJJoF (2021) Antifungal drug susceptibility and genetic characterization of fungi recovered from COVID-19 patients. 7 (7):552","DOI":"10.3390\/jof7070552"},{"key":"5185_CR40","doi-asserted-by":"crossref","unstructured":"Verweij PE, Gangneux J-P, Bassetti M, Br\u00fcggemann RJ, Cornely OA, Koehler P, Lass-Fl\u00f6rl C, van de Veerdonk FL, Chakrabarti A, Hoenigl MJTLM (2020) Diagnosing COVID-19-associated pulmonary aspergillosis. 1 (2):e53-e55","DOI":"10.1016\/S2666-5247(20)30027-6"},{"key":"5185_CR41","doi-asserted-by":"crossref","unstructured":"Shah B, Modi P, Sagar SRJLs (2020) In silico studies on therapeutic agents for COVID-19: drug repurposing approach. 252:117652","DOI":"10.1016\/j.lfs.2020.117652"},{"key":"5185_CR42","doi-asserted-by":"crossref","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei YJTl (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. 395 (10223):507\u2013513","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"5185_CR43","doi-asserted-by":"crossref","unstructured":"White L, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, Pandey M, Whitaker H, May A, Morgan M (2020) A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU","DOI":"10.2139\/ssrn.3644400"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-022-05185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-022-05185-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-022-05185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:14:48Z","timestamp":1744200888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-022-05185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["5185"],"URL":"https:\/\/doi.org\/10.1007\/s00894-022-05185-w","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"193"}}